Abstracts for the 2017 Annual Meeting of the American Society for Clinical Oncology (ASCO) were released on Wednesday, May 17. Below are abstracts that discuss ROS1 cancers. The list does not include abstracts that discuss or compare methods to detect ROS1 if those abstracts will not be presented at the conference.
Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer.
Results indicate ROS1+ non-small cell lung cancer patients on crizotinib whose ROS1 gene fusion partner was not CD74 had better overall survival than ROS1-CD74 patients.
Distribution of receptor tyrosine kinase (RTK) nsSNPs in breast cancer (BC) patients (pts) using next-generation sequencing (NGS).
Metastatic breast cancer patients had frequent mutations in potentially actionable genes such as ROS1 and ALK, though few mutations were in molecular regions targetable by existing tyrosine kinase inhibitors.
Accelerating clinical trial enrollment with comprehensive genomic profiling (CGP) and just-in-time clinical trial sites: An index case of a paradigm shift.
“Just in Time” clinical trial design may allow ROS1 patients to enroll in clinical trials at nearby sites instead of traveling to distant academic cancer centers.
The age specific genomic landscape of cancer.
Alterations in some oncogenes (including ROS1) were more common in patients younger than age 60 in this study.
Characterization of tumor mutation load (TML) in solid tumors.
Presence of mutations in ROS1 and other oncogenic driver genes correlated with lower tumor mutational load in non-small cell lung cancer.
Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.
ROS1 mutations were found in 3% of spitzoid melanomas studied.
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).
Genomic profiling of circulating tumor DNA via liquid biopsy detected ROS1 and other genomic alterations in blood collected from NSCLC patients.
ABSTRACTS PUBLISHED BUT NOT PRESENTED AT ASCO 2017
Mutational profiling of Chinese ROS1 positive non-small cell lung cancer patients with required resistant to crizotinib by next generation sequencing.
Mutational profiles of sixteen ROS1+NSCLC patients who had developed crizotinib resistance.
Next generation sequencing (NGS) in wild type GISTs.
A ROS1 mutation was found in wild-type GIST cancer
Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).
ROS1 fusions were detected in 4% of non-squamous non-small cell lung cancer patients in a large Japanese cohort, and patients who received targeted agents showed significantly longer survivals.
Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes.
The use of targeted therapy or immunotherapy was associated with increased overall survival in this group of non-squamous non-small cell lung cancer patients with brain mets.
Distribution and pathogenicity of nsSNPs in receptor tyrosine kinases (RTKs) in patients with colorectal cancer.
ROS1 mutations were among those found in a cohort of colorectal cancer patients.